Cidara Therapeutics Inc (CDTX)
13.00
+0.17
(+1.33%)
USD |
NASDAQ |
Oct 31, 16:00
13.00
0.00 (0.00%)
After-Hours: 20:00
Cidara Therapeutics Cash from Operations (TTM): -124.78M for June 30, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
June 30, 2024 | -124.78M |
March 31, 2024 | -18.18M |
December 31, 2023 | -22.43M |
September 30, 2023 | -30.71M |
June 30, 2023 | -1.105M |
March 31, 2023 | -15.76M |
December 31, 2022 | -28.47M |
September 30, 2022 | -22.38M |
June 30, 2022 | -62.32M |
March 31, 2022 | -47.05M |
December 31, 2021 | -25.23M |
September 30, 2021 | -21.45M |
June 30, 2021 | -23.56M |
March 31, 2021 | -41.08M |
December 31, 2020 | -54.41M |
September 30, 2020 | -58.48M |
June 30, 2020 | -27.78M |
March 31, 2020 | -26.51M |
December 31, 2019 | -28.53M |
September 30, 2019 | -27.00M |
Date | Value |
---|---|
June 30, 2019 | -56.40M |
March 31, 2019 | -59.13M |
December 31, 2018 | -56.70M |
September 30, 2018 | -52.53M |
June 30, 2018 | -53.61M |
March 31, 2018 | -50.11M |
December 31, 2017 | -49.91M |
September 30, 2017 | -52.14M |
June 30, 2017 | -45.96M |
March 31, 2017 | -43.40M |
December 31, 2016 | -39.77M |
September 30, 2016 | -34.78M |
June 30, 2016 | -34.40M |
March 31, 2016 | -30.79M |
December 31, 2015 | -25.96M |
September 30, 2015 | -22.39M |
June 30, 2015 | -18.31M |
March 31, 2015 | -13.35M |
December 31, 2014 | -7.71M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-124.78M
Minimum
Jun 2024
-1.105M
Maximum
Jun 2023
-35.80M
Average
-27.78M
Median
Jun 2020
Cash from Operations (TTM) Benchmarks
Biomarin Pharmaceutical Inc | 414.70M |
Arbutus Biopharma Corp | -72.88M |
GlycoMimetics Inc | -35.70M |
FibroGen Inc | -202.02M |
Cue Biopharma Inc | -38.53M |